Porreca Angelo, Di Gianfrancesco Luca, Artibani Walter, Busetto Gian Maria, Carrieri Giuseppe, Antonelli Alessandro, Bianchi Lorenzo, Brunocilla Eugenio, Bocciardi Aldo Massimo, Carini Marco, Celia Antonio, Cochetti Giovanni, Gallina Andrea, Mearini Ettore, Minervini Andrea, Schiavina Riccardo, Serni Sergio, D'Agostino Daniele, Debbi Erica, Corsi Paolo, Crestani Alessandro
Oncological Urology, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy.
Department of Urology, Policlinico Abano Terme, Abano Terme, Italy.
Cent European J Urol. 2022;75(2):135-144. doi: 10.5173/ceju.2022.0284. Epub 2022 May 4.
The Italian Radical Cystectomy Registry (Registro Italiano Cistectomie - RIC) aimed to analyse outcomes of a multicenter series of patients treated with radical cystectomy (RC) for bladder cancer.
An observational, prospective, multicenter, cohort study was performed to collect data from RC and urinary diversion via open (ORC), laparoscopic (LRC), or robotic-assisted (RARC) techniques performed in 28 Italian Urological Departments. The enrolment was planned from January 2017 to June 2020 (goal: 1000 patients), with a total of 1425 patients included. Chi-square and t-tests were used for categorical and continuous variables. All tests were 2-sided, with a significance level set at p <0.05.
Overall median operative-time was longer in RARCs (390 minutes, IQR 335-465) than ORCs (250, 217-309) and LRCs (292, 228-350) (p <0.001). Lymph node dissection (LND) was performed more frequently in RARCs (97.1%) and LRCs (93.5%) than ORCs (85.6%) (p <0.001), with extended-LND performed 2-fold more frequently in RARCs (61.6%) (p <0.001). The neobladder rate was significantly higher (more than one-half) in RARCs. The median estimated blood loss (EBL) rate was lower in RARCs (250 ml, 165-400) than LRCs (330, 200-600) and ORCs (400, 250-600) (p <0.001), with intraoperative blood transfusion rates of 11.4%, 21.7% and 35.6%, respectively (p <0.001). The conversion to open rate was slightly higher in RARCs (6.8%) than LRCs (4.3%). Intraoperative complications occurred in 1.3% of cases without statistically significant differences among the approaches.
Data from the RIC confirmed the need to collect as much data as possible in a multicenter manner. RARCs proves to be feasible with perioperative complication rates that do not differ from the other approaches.
意大利根治性膀胱切除术登记处(Registro Italiano Cistectomie - RIC)旨在分析多中心系列膀胱癌根治性膀胱切除术(RC)患者的治疗结果。
进行了一项观察性、前瞻性、多中心队列研究,以收集28个意大利泌尿外科科室采用开放手术(ORC)、腹腔镜手术(LRC)或机器人辅助手术(RARC)进行RC及尿流改道的数据。计划于2017年1月至2020年6月进行入组(目标:1000例患者),共纳入1425例患者。卡方检验和t检验用于分类变量和连续变量。所有检验均为双侧检验,显著性水平设定为p<0.05。
RARC组的总体中位手术时间(390分钟,IQR 335 - 465)长于ORC组(250分钟,217 - 309)和LRC组(292分钟,228 - 350)(p<0.001)。RARC组(97.1%)和LRC组(93.5%)进行淋巴结清扫(LND)的频率高于ORC组(85.6%)(p<0.001),RARC组进行扩大淋巴结清扫的频率是ORC组的2倍(61.6%)(p<0.001)。RARC组的新膀胱率显著更高(超过一半)。RARC组的中位估计失血量(EBL)率(250 ml,165 - 400)低于LRC组(330 ml,200 - 600)和ORC组(400 ml,250 - 600)(p<0.001),术中输血率分别为11.4%、21.7%和35.6%(p<0.001)。RARC组的中转开放率(6.8%)略高于LRC组(4.3%)。1.3%的病例发生术中并发症,各手术方式之间无统计学显著差异。
RIC的数据证实了以多中心方式尽可能收集数据的必要性。RARC被证明是可行的,围手术期并发症发生率与其他手术方式无差异。